Frequency and clinicoeconomic impact of delays to definitive diagnosis of obstructive hypertrophic cardiomyopathy in the United States
Naidu S, Sutton M, Gao W, Fine J, Xie J, Desai N, Owens A. Frequency and clinicoeconomic impact of delays to definitive diagnosis of obstructive hypertrophic cardiomyopathy in the United States. Journal Of Medical Economics 2023, 26: 682-690. PMID: 37170479, DOI: 10.1080/13696998.2023.2208966.Peer-Reviewed Original ResearchConceptsObstructive hypertrophic cardiomyopathyDefinitive diagnosisHypertrophic cardiomyopathyHCM diagnosisMedicare Supplemental databasesIBM MarketScan CommercialEmergency room visitsAdministrative claims dataMisclassification of patientsEligible patientsMarketScan CommercialMost patientsRoom visitsAlternative diagnosesPotential misdiagnosesCardiovascular conditionsInappropriate treatmentDatabase studyClaims dataHealthcare costsDiagnostic journeyPatientsEconomic burdenCurrent studyDiagnostic historyClinical Outcomes, Resource Utilization, and Treatment Over the Disease Course of Symptomatic Obstructive Hypertrophic Cardiomyopathy in the United States
Desai N, Sutton M, Xie J, Fine J, Gao W, Owens A, Naidu S. Clinical Outcomes, Resource Utilization, and Treatment Over the Disease Course of Symptomatic Obstructive Hypertrophic Cardiomyopathy in the United States. The American Journal Of Cardiology 2023, 192: 16-23. PMID: 36709525, DOI: 10.1016/j.amjcard.2022.12.030.Peer-Reviewed Original ResearchConceptsObstructive hypertrophic cardiomyopathyHypertrophic cardiomyopathyIndex dateCardiovascular eventsIncidence rateSymptomatic obstructive hypertrophic cardiomyopathyAtrial fibrillation/flutterCommon cardiovascular eventMonths continuous eligibilityHealthcare resource utilizationMedicare Supplemental databasesIBM MarketScan CommercialEligible patientsDiagnosis dateMarketScan CommercialClinical outcomesContinuous eligibilityTreatment optionsCumulative riskPatientsResource utilizationPharmacotherapyCardiomyopathyDisease